文献速递妇科肿瘤

ENGOT-ov-6/TRINOVA-2:聚乙二醇脂质体多柔比星联合曲巴尼布或安慰剂治疗复发性部分铂敏感或铂耐药卵巢癌女性的随机双盲3期研究

ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer.
PubMed 文献 · Eur J Cancer · 2016-12-01

这项随机双盲安慰剂对照3期研究纳入223例铂无治疗间期≤12个月的复发性上皮性卵巢癌患者,比较聚乙二醇脂质体多柔比星联合曲巴尼布或安慰剂的疗效。曲巴尼布组客观缓解率为46% vs 安慰剂组21%(比值比3.43,95%CI 1.78-6.64),中位缓解持续时间7.4个月 vs 3.9个月,但中位无进展生存期未改善(7.6个月 vs 7.2个月,风险比0.92,95%CI 0.68-1.24)。

要点

  • 曲巴尼布组客观缓解率46% vs 安慰剂组21%,比值比3.43(95%CI 1.78-6.64)。
  • 曲巴尼布组中位缓解持续时间7.4个月 vs 安慰剂组3.9个月。
  • 中位无进展生存期曲巴尼布组7.6个月 vs 安慰剂组7.2个月,未改善。

核心结论

  • 曲巴尼布在这项3期研究中显示出抗癌活性,表现为客观缓解率和缓解持续时间改善,但中位无进展生存期未改善,未发现新的安全性信号。

研究设计与样本

  • 随机、双盲、安慰剂对照3期研究,纳入223例复发性卵巢癌女性,铂无治疗间期≤12个月。
  • 患者随机接受静脉聚乙二醇脂质体多柔比星50 mg/m2每4周一次联合每周静脉曲巴尼布15 mg/kg或安慰剂。
  • 主要终点为无进展生存期,关键次要终点为客观缓解率和缓解持续时间。
  • 因聚乙二醇脂质体多柔比星短缺,入组暂停13个月,研究随后被截断。

主要发现

  • 中位无进展生存期曲巴尼布组7.6个月(95%CI 7.2-9.0) vs 安慰剂组7.2个月(95%CI 4.8-8.2),风险比0.92(95%CI 0.68-1.24)。
  • 因比例风险假设不满足,标准Cox模型未能提供可靠的风险比估计。
  • 客观缓解率曲巴尼布组46% vs 安慰剂组21%(比值比3.43,95%CI 1.78-6.64)。
  • 中位缓解持续时间曲巴尼布组7.4个月(95%CI 5.7-7.6) vs 安慰剂组3.9个月(95%CI 2.3-6.5)。
  • 曲巴尼布组发生率更高的不良事件包括局限性水肿(61% vs 32%)、腹水(29% vs 9%)和呕吐(45% vs 33%)。

局限性

  • 因聚乙二醇脂质体多柔比星短缺,入组暂停13个月,研究随后被截断。
  • 因比例风险假设不满足,标准Cox模型未能提供可靠的风险比估计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Trebananib, a peptide-Fc fusion protein, inhibits angiogenesis by inhibiting binding of angiopoietin-1/2 to the receptor tyrosine kinase Tie2. This randomised, double-blind, placebo-controlled phase 3 study evaluated whether trebananib plus pegylated liposomal doxorubicin (PLD) improved progression-free survival (PFS) in patients with recurrent epithelial ovarian cancer. METHODS: Women with recurrent ovarian cancer (platinum-free interval ≤12 months) were randomised to intravenous PLD 50 mg/m2 once every 4 weeks plus weekly intravenous trebananib 15 mg/kg or placebo. PFS was the primary end-point; key secondary end-points were objective response rate (ORR) and duration of response (DOR). Owing to PLD shortages, enrolment was paused for 13 months; the study was subsequently truncated. RESULTS: Two hundred twenty-three patients were enrolled. Median PFS was 7.6 months (95% CI, 7.2-9.0) in the trebananib arm and 7.2 months (95% CI, 4.8-8.2) in the placebo arm, with a hazard ratio of 0.92 (95% CI, 0.68-1.24). However, because the proportional hazards assumption was not fulfilled, the standard Cox model did not provide a reliable estimate of the hazard ratio. ORR in the trebananib arm was 46% versus 21% in the placebo arm (odds ratio, 3.43; 95% CI, 1.78-6.64). Median DOR was improved (trebananib, 7.4 months [95% CI, 5.7-7.6]; placebo, 3.9 months [95% CI, 2.3-6.5]). Adverse events with a greater incidence in the trebananib arm included localised oedema (61% versus 32%), ascites (29% versus 9%) and vomiting (45% versus 33%). CONCLUSIONS: Trebananib demonstrated anticancer activity in this phase 3 study, indicated by improved ORR and DOR. Median PFS was not improved. No new safety signals were identified. TRIAL REGISTRATION: ClinicalTrials.gov, NCT01281254.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Marth C, Vergote I, Scambia G, et al. ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer. Eur J Cancer. 2016. PMID: 27914241. doi:10.1016/j.ejca.2016.09.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。